<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255070</url>
  </required_header>
  <id_info>
    <org_study_id>ARX788-1711</org_study_id>
    <nct_id>NCT03255070</nct_id>
  </id_info>
  <brief_title>A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)</brief_title>
  <official_title>A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ambrx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ambrx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of&#xD;
      ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and&#xD;
      anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1a will determine the recommended Phase 2 dose (RP2D) in subjects with advanced cancer&#xD;
      whose HER2 test results are in situ hybridization (ISH) positive or immunohistochemistry&#xD;
      (IHC) 3+, based on safety, tolerability, PK findings and antitumor activity. Phase 1b will&#xD;
      assess the safety, tolerability, and PK and anticancer activity in five expansion cohorts,&#xD;
      including breast cancer, gastric cancer / gastroesophageal adenocarcinoma, and other advanced&#xD;
      HER2-positive solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a 2-part, Phase 1, open-label study will administer the IMP, ARX788 by IV infusion every 3, 4 or 6 weeks. Sequential dose escalation cohorts are planned using a 3+3 design. A cohort may be expanded to collect additional data if recommended by Safety Monitoring Committee based on comprehensive reviews of safety, tolerability and PK data to determine RP2D.&#xD;
Phase 1a will determine the recommended Phase 2 dose (RP2D) in subjects with advanced cancer whose HER2 test results are in situ hybridization (ISH) positive or immunohistochemistry (IHC) 3+.&#xD;
Phase 1b will assess anticancer activity and safety in advanced cancer.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects experiencing adverse events, frequency and seriousness of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Day 1 through 30 days after last dose</time_frame>
    <description>To assess the safety, tolerability, and immunogenicity profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.</measure>
    <time_frame>36 months</time_frame>
    <description>Number of subjects with objective response is assessed every 6-8 weeks from Cycle 1 Day 1 through disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with tumor response per imaging assessment based on RECIST version 1.1.</measure>
    <time_frame>18 months</time_frame>
    <description>The objective response rate (ORR: CR+PR) based on RECIST v1.1 will be assessed as the primary endpoint to determine the anticancer activity of ARX788 as well as best overall response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) from first infusion to subject end of study.</measure>
    <time_frame>36 months</time_frame>
    <description>Pharmacokinetic (PK) characteristics: ARX788 (intact ADC), total mAb, and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of ARX788 from first infusion to end of study.</measure>
    <time_frame>36 months</time_frame>
    <description>Pharmacokinetic (PK) characteristics: ARX788 from first infusion to subject end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile of ARX788</measure>
    <time_frame>36 months</time_frame>
    <description>Number of subjects who develop anti-ARX788 antibody</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Gastric Neoplasm</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ARX788 Phase 1a (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARX788 will be administered every 3 weeks (Q3W) or every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will be enrolled into escalating dose levels during Dose Escalation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARX788 Phase 1b (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARX788 will be administered every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARX788</intervention_name>
    <description>An antibody drug conjugate</description>
    <arm_group_label>ARX788 Phase 1a (Dose Escalation)</arm_group_label>
    <arm_group_label>ARX788 Phase 1b (Dose Expansion)</arm_group_label>
    <other_name>antibody drug conjugate (ADC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Life expectancy &gt;3 months.&#xD;
&#xD;
          -  Female or male subjects whose advanced HER2 expressing cancer has failed standard of&#xD;
             care treatments, or for whom such therapy is not acceptable to the subject. Subjects&#xD;
             with advanced breast, gastric cancer, or other solid tumor who test positive for HER2&#xD;
             by ASCO/CAP criteria (either IHC or FISH) must have received prior treatment with a&#xD;
             trastuzumab containing therapy. Subjects who have been previously treated with&#xD;
             pertuzumab, TDM-1, lapatinib, or other available and accessible HER2-directed&#xD;
             therapies or investigational therapies are eligible.&#xD;
&#xD;
          -  Disease measurability:&#xD;
&#xD;
               -  Phase 1a: measurable or non-measurable disease per RECIST v 1.1.&#xD;
&#xD;
               -  Phase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable&#xD;
                  disease are not eligible for Phase 1b).&#xD;
&#xD;
          -  Histopathologic evidence of cancer based upon pathology report.&#xD;
&#xD;
          -  Tumor tissue local laboratory HER2 testing results, adequate tumor sample available&#xD;
             for confirmation of HER2 status. Subjects with other types of cancer must have&#xD;
             previously tested locally for HER2 status by HER2 IHC or ISH assay.&#xD;
&#xD;
               -  Phase 1a: ISH positive or IHC 3+ advanced cancer (including breast or&#xD;
                  gastric/esophageal or other solid tumors).&#xD;
&#xD;
               -  Phase 1b: Cohort 8 advanced breast cancer (IHC 3+ or IHC 2+/ISH); Cohort 9&#xD;
                  advanced breast cancer (IHC 2+ / ISH-); Cohort 10 advanced gastric cancer (IHC 3+&#xD;
                  or IHC 2+/ISH+) or gastroesophageal junction adenocarcinoma; Cohort 11 other&#xD;
                  advanced solid tumor cancers with HER2-overexpression (HER2 IHC 3+ or IHC&#xD;
                  2+/IHS+); Cohort 12 advanced solid tumor cancers with HER2 activating mutation.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status of 0 to 1.&#xD;
&#xD;
          -  Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved&#xD;
             to Grade 0 or 1 as per the NCI-CTCAE v 4.03 (phase 1a) and v 5.0 ( Phase 1b).&#xD;
&#xD;
          -  Adequate organ functions.&#xD;
&#xD;
          -  Willing and able to understand and sign an informed consent inform and to comply with&#xD;
             all aspects of the protocol.&#xD;
&#xD;
          -  Female subjects must be surgically sterile, or have a monogamous partner who is&#xD;
             surgically sterile, or at least 2 years postmenopausal, or who commits to use an&#xD;
             acceptable form of birth control (defined as the use of an intrauterine device, a&#xD;
             barrier method with spermicide, condoms, any form of hormonal contraceptives, or&#xD;
             abstinence) for the duration of the study and for 3 months following the last dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  Male subjects must be sterile (biologically or surgically) or commit to the use of a&#xD;
             reliable method of birth control (condoms with spermicide) for the duration of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergic reactions to any component of ARX788.&#xD;
&#xD;
          -  History of ocular events, or any current ongoing active ocular infections.&#xD;
&#xD;
          -  History of congestive heart failure, unstable angina pectoris, unstable atrial&#xD;
             fibrillation, or cardiac arrhythmia within 12 months prior to enrollment&#xD;
&#xD;
          -  Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 5.0)&#xD;
&#xD;
          -  History of unstable central nervous system (CNS) metastases&#xD;
&#xD;
          -  Current severe, uncontrolled systemic disease (eg, clinical significant&#xD;
             cardiovascular, pulmonary, or metabolic diseases)&#xD;
&#xD;
          -  Any uncontrollable intercurrent illness, infection (including subjects with active,&#xD;
             symptomatic Covid-19 infections), or other conditions that could limit study&#xD;
             compliance or interfere with assessments.&#xD;
&#xD;
          -  Exposure to any other investigational or commercial anticancer agents or therapies&#xD;
             administered with the intention to treat malignancy within 14 days before the first&#xD;
             dose of ARX788.&#xD;
&#xD;
          -  Clinically significant surgical intervention (excluding diagnostic biopsy) within 21&#xD;
             days of the first dose of ARX788&#xD;
&#xD;
          -  Radiotherapy administered less than 21 days prior to the first dose of ARX788, or&#xD;
             localized palliative radiotherapy administered less than 7 days prior to the first&#xD;
             dose of ARX788, or radiotherapy-induced toxicity of Grade 2 or greater based on&#xD;
             NCI-CTCAE v 5.0.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Known active HCV, HBV, and/or HIV infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ambrx</last_name>
    <role>Study Director</role>
    <affiliation>Ambrx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Inquiry</last_name>
    <phone>858-875-2400</phone>
    <email>pantumor01trialinquiry@ambrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC Norris Cancer Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Lu, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Janice Lu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology-Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Hurvitz, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Sara Hurvitz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haeseong Park, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Haeseong Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Budd, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Budd, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce O'Shaughnessy, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Joyce O'Shaughnessy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albury Wodonga University Hospital</name>
      <address>
        <city>East Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Eek, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Richard Eek, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Limited</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Shannon, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Catherine Shannon, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandria Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharine Cuff, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Katharine Cuff, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Frentzas, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Sophia Frentzas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>antibody drug conjugate</keyword>
  <keyword>breast cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>advanced solid tumors</keyword>
  <keyword>HER2-overexpression</keyword>
  <keyword>HER2-mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

